DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer.

AIM This single institution Phase II study evaluated drug-eluting beads loaded with irinotecan (DEBIRI) plus capecitabine in pretreated patients with colorectal cancer liver metastases. PATIENTS & METHODS Forty patients with liver-limited or liver-dominant disease, who have failed at least two previous lines of chemotherapy, underwent either four DEBIRI… CONTINUE READING